Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
BioVaxys Technology ( (TSE:BIOV) ) has shared an announcement.
BioVaxys Technology Corp. has announced an extension to the closing date of its non-brokered private placement offering, originally set for February 7, 2025, and now extended to February 14, 2025. This extension aims to allow additional investors to engage in the final tranche, with proceeds intended for working capital. The announcement could enhance BioVaxys’ financial flexibility and operational capacity, potentially strengthening its market position and offering stakeholders a more robust platform for future developments.
More about BioVaxys Technology
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company based in British Columbia, Canada. It focuses on developing novel immunotherapies using its DPX™ immune-educating technology platform and HapTenix© ‘neoantigen’ tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immunological fields. The company’s innovative DPX™ platform is designed to deliver antigens to lymph nodes, inducing strong and lasting immune responses, and its shares are traded on the Canadian Securities Exchange, Frankfurt Bourse, and quoted in the US on OTC Markets.
YTD Price Performance: -16.00%
Average Trading Volume: 500,057
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $9.84M
Find detailed analytics on BIOV stock on TipRanks’ Stock Analysis page.
